Transforming vaccines with breakthrough VLP technology

Corporate profile

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and its pipeline includes additional programs in influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.

Press releases

September 19, 2023
Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
August 14, 2023
Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 8, 2023
Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential


September 26, 2023
Cantor Fitzgerald Global Healthcare Conference 2023
May 22, 2023 at 6:00 PM EDT
Icosavax Investor Call
March 13, 2023 at 12:40 PM EDT
Oppenheimer 33rd Annual Healthcare Conference

Latest presentation

September 2023
Icosavax September 2023 Corporate Presentation
Investor Email Alerts